Compare Recursion Pharmaceuticals Inc (RXRX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Schlumberger NV — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B), while Schlumberger NV trades at $57.07 (market cap $84.74B). The key difference: Schlumberger NV is far larger — about 45.6× Recursion Pharmaceuticals Inc's market cap, and Schlumberger NV pays a 2.07% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SLB | |
|---|---|---|
Market Cap | $1.86B | $84.74B |
Sector | Health | Energy |
52-Week High | $6.79 | $60.10 |
52-Week Low | $2.84 | $31.72 |
Enterprise Value | $1.38B | $93.47B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
SLB trades at $57.10, down 0.71% on the day, with strong analyst support (85% buy ratings) and a $63.50 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a strategic $3.4 billion acquisition of Kelvion to expand into data center cooling technology. Revenue remains stable at $35.7 billion (2025) with solid profitability metrics including 8.53% net margin and 13.37% ROE.
The outlook remains positive with diversification into high-growth data center markets, though risks include oil price volatility and execution challenges from recent acquisitions. Current valuation at 27.85 P/E appears reasonable given growth initiatives, supporting a constructive view for long-term investors despite near-term market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
